Analysis and suggestions for the FDA drug labeling rules on cardiac safety risk warnings
1a.Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China
1b.Drug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China
1c.Department of Cardiology and Institute of Vascular Medicine, National Health Commission Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Key Laboratory of Molecular Cardiovascular Science, Ministry of Education, Beijing Key Laboratory of Cardiovascular Receptors Research, Peking University Third Hospital, Beijing 100191, China
2.Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
3.Department of Pharmacy, Hebei General Hospital, Shijiazhuang 050057, Hebei Province, China
4.Department of Pharmacy, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710004, Shaanxi Province, China
5.Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China
6.Department of Pharmacy, The Fifth Clinical Medical College of Henan University of Chinese Medicine / Zhengzhou People’s Hospital, Zhengzhou 450003, Henan Province, China
收起